Centessa Pharmaceuticals, a wholly subsidiary of Eli Lilly and Company is advancing a portfolio of high conviction programs with strong biological validation. Our asset-centric model offers a unique R&D logic that has been applied by single asset companies to improve productivity. This operating model has minimal centralized infrastructure, reduced hierarchy, and exclusive focus on data driven capital allocation. Our teams are uniquely incentivized to expeditiously interrogate key scientific hypotheses. We believe the asset-centric model can lead to improved success rates for programs with greater speed and modest costs. Centessa Pharmaceuticals is seeking an Executive Director, Toxicology to provide scientific and strategic leadership as well as operational management for nonclinical safety across discovery and development programs, with an emphasis on small‑molecule therapeutics. This role leads toxicology and safety pharmacology strategy to support target selection, lead optimization, IND/NDA enabling activities. Reporting to our Head of Nonclinical & Translational Development, the Executive Director partners closely with cross‑functional teams and represents nonclinical safety in regulatory interactions while building a strong, high‑performing toxicology organization.
Stand Out From the Crowd
Upload your resume and get instant feedback on how well it matches this job.
Job Type
Full-time
Career Level
Executive
Education Level
Ph.D. or professional degree